Epstein–Barr virus neutralizing antibody levels and risk of multiple sclerosis

Abstract

Previous infection with Epstein–Barr virus (EBV) and infectious mononucleosis are established multiple sclerosis (MS) risk factors, and elevated serum titers of anti-EBV nuclear antigen (anti-EBNA) antibodies in healthy adults are strongly correlated with future MS risk. In this prospective study, we investigated the association between EBV neutralizing antibodies and MS risk. MS risk tended to be higher in individuals with high titers of neutralizing antibodies compared to those with low titers (relative risk [RR] = 2.2, 95% confidence interval [CI] 0.97–5.1). This association was attenuated after adjustment for anti-EBNA1 IgG Ab titers (RR = 1.4, 95% CI 0.5–3.5). This preliminary finding warrants further study in a larger population.

Keywords

Epstein–Barr nuclear antigen Epstein–Barr virus glycoprotein 350 infectious mononucleosis multiple sclerosis neutralizing antibodies

Get full access to this article

View all access options for this article.

References

Levin

Munger

O’Reilly

Falk

Ascherio

. Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67: 824–830.

Ascherio

Munger

. Epstein–Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 2010; 5: 271–277.

Ascherio

Munger

. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol 2007; 61: 288–299.

Morgan

Khanna

. EBV: vaccines and immunotherapy. In: Arvin

Campadelli-Fumi

Mocarski

, et al. (eds.), Human Herpesviruses: Biology, Therapy and Immunoprophylaxis. Cambridge: Cambridge University Press, 2007.

Nemerow

Mold

Schwend

Tollefson

Cooper

. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein–Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol 1987; 61: 1416–1420.

Sokal

Hoppenbrouwers

Vandermeulen

, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196: 1749–1753.

Lindsey

Hatfield

. Epstein–Barr virus neutralizing and early antigen antibodies in multiple sclerosis. Eur J Neurol 2010; 17: 1263–1269.

Ascherio

Munger

Lennette

, et al. Epstein–Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA 2001; 286: 3083–3088.

Wilson

Morgan

. Indirect measurement of Epstein–Barr virus neutralising antibodies by ELISA. J Virol Methods 1998; 73: 11–19.